100 - Refining & Repurposing Treatments for Alzheimer's Disease: September 2020

<p>Can you believe this is our 100th episode??? It has been a little over 6 months since our official launch and we are now running full steam, thanks to a hardworking team. Cheers to the members of AMiNDR, and cheers to you for listening to us. </p><p>This episode is for those of you who are interested in what’s already on the marker for treating Alzheimer’s diseases. That’s right, you have knowingly or by chance stumbled upon our episode on refining or repurposing existing medications, as well as improving methods of drug delivery. You will hear about advances in refining the use of Memantine, Donepezil, and Rivastigmine, and exploring the potential of drugs like Lithium, Escitalopram, or Sildenafil to alleviate the symptoms of AD. We also cover papers that look at refining methods of drug delivery, efficiency, or bioavailability. </p><p><strong>Sections in this episode:  </strong></p><p><strong>Section 1: Refining existing drugs 3.53 </strong><br />Memantine (1 paper): 4.26 <br />Donepezil (3 papers): 6.03 <br />Rivastigmine (1 paper): 12.55 </p><p><strong>Section 2: Refining methods (delivery, efficiency, bioavailability): (5 papers) 15.25 </strong></p><p><strong>Section 3: Repurposing approved drugs (6 papers): 28.26 </strong></p><p><strong>Bonus paper: 43.29 </strong></p><p>------------------------------------------------------------------ </p><p>To receive the list of papers covered, please fill this form:  </p><p>-------->  https://forms.gle/CVVbznAFM8pamdgk6  -------  </p><p>or by tweeting at us: @AMiNDR_podcast  </p><p>------------------------------------------------------------------ </p><p>We would appreciate your feedback so we can better cater to your needs.  </p><p>You can fill our feedback form here  </p><p>---------->  https://forms.gle/5aq2JyrT6g4P1m8v6 </p><p> </p><p>You can also share your thoughts and suggestions by contacting us:  </p><p>Email: amindrpodcast@gmail.com  </p><p>Facebook:  <a href="https://www.facebook.com/amindrpodcast" target="_blank">AMiNDR</a>  </p><p>Twitter: <a href="http